Syncom Formulations (India) Limited (SYNCOMF.NS)
INR 21.04
(-0.14%)
INR 21.04
(-0.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.16 Billion INR | -4.35% |
| 2022 | 1.21 Billion INR | 41.62% |
| 2021 | 860.16 Million INR | -17.34% |
| 2020 | 1.04 Billion INR | 198.41% |
| 2019 | 348.73 Million INR | -13.57% |
| 2018 | 403.48 Million INR | -17.7% |
| 2017 | 490.26 Million INR | -21.96% |
| 2016 | 628.17 Million INR | -5.83% |
| 2015 | 667.06 Million INR | 78.45% |
| 2014 | 373.82 Million INR | -16.63% |
| 2013 | 448.4 Million INR | 27.51% |
| 2012 | 351.66 Million INR | 20.7% |
| 2011 | 291.34 Million INR | -7.24% |
| 2010 | 314.08 Million INR | -15.73% |
| 2009 | 372.72 Million INR | 68.09% |
| 2008 | 221.73 Million INR | -23.4% |
| 2007 | 289.47 Million INR | 46.94% |
| 2006 | 197 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.16 Billion INR | 0.0% |
| 2023 FY | 1.16 Billion INR | -4.35% |
| 2023 Q2 | 1.33 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 1.21 Billion INR | 0.0% |
| 2022 FY | 1.21 Billion INR | 41.62% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 1.34 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 981.34 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 860.16 Million INR | -17.34% |
| 2021 Q4 | 860.16 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 1.04 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 638.13 Million INR | 0.0% |
| 2020 FY | 1.04 Billion INR | 198.41% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 422.9 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 348.73 Million INR | -13.57% |
| 2019 Q4 | 348.73 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 360.28 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 403.48 Million INR | -17.7% |
| 2018 Q4 | 403.48 Million INR | 0.0% |
| 2017 FY | 490.26 Million INR | -21.96% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 490.26 Million INR | 0.0% |
| 2016 Q4 | 628.17 Million INR | 0.0% |
| 2016 FY | 628.17 Million INR | -5.83% |
| 2015 FY | 667.06 Million INR | 78.45% |
| 2015 Q4 | 667.06 Million INR | 0.0% |
| 2015 Q2 | 284.55 Million INR | 0.0% |
| 2014 Q4 | 373.82 Million INR | 0.0% |
| 2014 Q2 | 374.07 Million INR | 0.0% |
| 2014 FY | 373.82 Million INR | -16.63% |
| 2013 Q4 | 448.4 Million INR | 0.0% |
| 2013 FY | 448.4 Million INR | 27.51% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 300.67 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 FY | 351.66 Million INR | 20.7% |
| 2012 Q2 | 539.9 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 351.66 Million INR | 0.0% |
| 2011 FY | 291.34 Million INR | -7.24% |
| 2010 FY | 314.08 Million INR | -15.73% |
| 2009 FY | 372.72 Million INR | 68.09% |
| 2008 FY | 221.73 Million INR | -23.4% |
| 2007 FY | 289.47 Million INR | 46.94% |
| 2006 FY | 197 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | 53.967% |
| Ind-Swift Limited | 13.45 Billion INR | 91.339% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 76.062% |
| Sakar Healthcare Limited | 1.26 Billion INR | 7.763% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.234% |
| Innova Captab Limited | 4.89 Billion INR | 76.22% |
| Divi's Laboratories Limited | 18.99 Billion INR | 93.864% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 68.173% |
| Morepen Laboratories Limited | 4.45 Billion INR | 73.873% |
| Mankind Pharma Limited | 23.87 Billion INR | 95.119% |
| Sequent Scientific Limited | 8.27 Billion INR | 85.918% |
| Wanbury Limited | 3.15 Billion INR | 63.074% |
| Laurus Labs Limited | 42.71 Billion INR | 97.272% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 89.613% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 77.509% |
| Alembic Limited | 1.43 Billion INR | 18.636% |
| Hikal Limited | 12.99 Billion INR | 91.033% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 92.84% |
| Neuland Laboratories Limited | 5.49 Billion INR | 78.809% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 89.118% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.21% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 81.589% |
| Themis Medicare Limited | 1.88 Billion INR | 38.267% |
| RPG Life Sciences Limited | 1.38 Billion INR | 15.577% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 98.377% |
| Lupin Limited | 96.23 Billion INR | 98.789% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -48.657% |
| Wockhardt Limited | 39.87 Billion INR | 97.077% |
| Vaishali Pharma Limited | 371.16 Million INR | -213.935% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 85.877% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -292.644% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 98.098% |
| FDC Limited | 3.7 Billion INR | 68.586% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.911% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -80.966% |
| Eris Lifesciences Limited | 38.26 Billion INR | 96.955% |
| Venus Remedies Limited | 1.39 Billion INR | 16.34% |
| ZIM Laboratories Limited | 2.08 Billion INR | 44.001% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 44.747% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -629.209% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 66.761% |
| Shilpa Medicare Limited | 12.93 Billion INR | 90.99% |
| Albert David Limited | 1.15 Billion INR | -1.313% |
| Ajanta Pharma Limited | 10.71 Billion INR | 89.121% |
| Hester Biosciences Limited | 3.59 Billion INR | 67.585% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 42.72% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 91.731% |
| Gufic Biosciences Limited | 5.59 Billion INR | 79.192% |
| Windlas Biotech Limited | 1.76 Billion INR | 33.896% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 54.505% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 32.341% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 41.041% |
| Granules India Limited | 22.95 Billion INR | 94.924% |
| Aarti Drugs Limited | 11.5 Billion INR | 89.871% |
| Bal Pharma Limited | 2.51 Billion INR | 53.601% |
| Alkem Laboratories Limited | 48.6 Billion INR | 97.603% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.365% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -8.438% |
| Medicamen Biotech Limited | 940.36 Million INR | -23.91% |
| Unichem Laboratories Limited | 8.06 Billion INR | 85.56% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -78.637% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -303.468% |
| Valiant Laboratories Limited | 1.05 Billion INR | -10.106% |
| Orchid Pharma Limited | 3.84 Billion INR | 69.688% |
| Medico Remedies Limited | 438.24 Million INR | -165.882% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 49.105% |
| Ipca Laboratories Limited | 33.74 Billion INR | 96.547% |
| Brooks Laboratories Limited | 248.6 Million INR | -368.707% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.792% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.58% |
| NATCO Pharma Limited | 10.53 Billion INR | 88.936% |
| Suven Life Sciences Limited | 148.62 Million INR | -684.015% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 60.819% |
| Strides Pharma Science Limited | 37.68 Billion INR | 96.908% |
| Indoco Remedies Limited | 10.34 Billion INR | 88.734% |
| Alpa Laboratories Limited | 307.12 Million INR | -279.397% |
| Lasa Supergenerics Limited | 541.92 Million INR | -115.013% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 70.068% |